Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.53 USD
Change Today +0.04 / 2.68%
Volume 67.0K
CGNT On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cogentix medical inc (CGNT) Snapshot

Open
$1.47
Previous Close
$1.49
Day High
$1.58
Day Low
$1.47
52 Week High
12/11/14 - $6.10
52 Week Low
08/26/15 - $1.33
Market Cap
40.1M
Average Volume 10 Days
88.3K
EPS TTM
$-0.44
Shares Outstanding
26.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COGENTIX MEDICAL INC (CGNT)

Related News

No related news articles were found.

cogentix medical inc (CGNT) Related Businessweek News

No Related Businessweek News Found

cogentix medical inc (CGNT) Details

Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets products for the urology market and flexible endoscopy. The company offers Urgent PC neuromodulation system for the overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence; and Macroplastique, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. It also provides EndoSheath system, which combines endoscopic technology with a sterile and disposable microbial barrier for flexible endoscopy. The company operates primarily in the United States, the Netherlands, and the United Kingdom. It primarily serves physicians. Cogentix Medical, Inc. was founded in 1987 and is headquartered in Minnetonka, Minnesota.

211 Employees
Last Reported Date: 06/25/15
Founded in 1987

cogentix medical inc (CGNT) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $890.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $361.4K
Vice President of Corporate Development
Total Annual Compensation: $195.1K
Vice President of Disposable Operations
Total Annual Compensation: $170.0K
Vice President of Industrial Division
Total Annual Compensation: $155.0K
Compensation as of Fiscal Year 2015.

cogentix medical inc (CGNT) Key Developments

Cogentix Medical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Reaffirms Earnings Guidance for the Fiscal 2016

Cogentix Medical, Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net sales of $11,150,212 against $6,384,629 a year ago. Operating loss was $3,212,207 against $2,174,441 a year ago. Loss before income taxes was $3,551,182 against $2,170,518 a year ago. Net loss was $3,568,760 or $0.14 per basic and diluted share against $2,190,332 or $0.14 per basic and diluted share a year ago. For the fiscal first quarter of 2016, total revenue represented an increase of 75% as compared to $6.4 million in the prior year period, primarily attributable to the merger of Uroplasty and Vision-Sciences that was completed on March 31, 2015. On a pro forma combined basis, revenue increased 10% over the first quarter of last year. The negative impact of changes in foreign currency exchange rates reduced fiscal first quarter total revenue by $0.3 million. On a constant currency basis, overall pro forma combined revenue growth was 13% in the first quarter. The company reaffirming the guidance for the fiscal year 2016, the company expects total revenue in the range of $49.0 million to $51.0 million in fiscal 2016. Cost synergies of approximately $3.0 million in fiscal 2016, exclusive of non-cash purchase price accounting adjustments such as amortization of identifiable intangibles Cash operating loss, excluding merger-related costs, in the range of $2.0 million to $3.0 million in fiscal 2016 Cash flow positive from operations for the fiscal year ended March 31, 2017.

Cogentix Medical, Inc. to Report Q1, 2016 Results on Aug 10, 2015

Cogentix Medical, Inc. announced that they will report Q1, 2016 results at 4:30 PM, US Eastern Standard Time on Aug 10, 2015

Cogentix Medical, Inc., Q1 2016 Earnings Call, Aug 10, 2015

Cogentix Medical, Inc., Q1 2016 Earnings Call, Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGNT:US $1.53 USD +0.04

CGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,800 JPY -4.00
Boston Scientific Corp $17.07 USD +0.13
Coloplast A/S kr455.70 DKK +4.50
Olympus Corp ¥4,430 JPY -10.00
Urologix Inc $0.04 USD +0.005
View Industry Companies
 

Industry Analysis

CGNT

Industry Average

Valuation CGNT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COGENTIX MEDICAL INC, please visit www.cogentixmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.